Safety and efficacy of cagrilintide in combination with semaglutide for weight management: Results from a phase 2 randomized controlled trial
Category 2 status created a gray zone
the largest Phase IIb trial with 536 participants failed to meet its primary efficacy endpoint, leading to development discontinuation in 2007
But the questions surrounding dosing, cycling, neurological effects, and angiogenic risk are genuinely unresolved
Whether metabolic benefits (improved insulin sensitivity, reduced visceral fat) persist, partially reverse, or fully reverse is unknown
Hip Flexor Strains The iliopsoas complex, comprising the iliacus and psoas major muscles, frequently sustains strain injuries in athletes and active individuals